ClinicalTrials.gg
RecruitingNCT05616793Updated Feb 19, 2026

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

A Phase 1/2 interventional study of AAV8.hLCA5 in LCA5, sponsored by Opus Genetics, Inc. Recruiting at 2 sites in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Opus Genetics, Inc · Phase 1/2, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Retinal Degeneration with a site in United States — 11 open to participants now, 29 under way, 3 of them phase 3. Retinal Degeneration · United States.

Planned enrollment
47th of 62
22 · median 51
Started
2023
with 10 others
Phase 1/2
14 of 84
2 open now
Primary completion
2028-06
later than 18 of 26 live
Registered
66th of 84
by date

Among the 84 studies in Retinal Degeneration with a site in United States, this one is the 47th largest by planned enrollment of the 62 interventional ones that give a count, is one of 11 that started in 2023, is one of 14 in phase 1/2, reaches primary completion later than 18 of the 26 other live ones, and was the 66th registered.

Retinal Degeneration

132 studies on the registry are indexed under Retinal Degeneration; 23 are open to participants now.

Browse Retinal Degeneration studies →

Open to participants now

11 of the 84 studies in Retinal Degeneration with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Retinal Degeneration studies recruiting now, 10 (67%) set no upper age limit and 3 (20%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Retinal Degeneration with a site in United States, or all of them as a file.
02

Study summary

The goals of this clinical trial are assess the natural course of LCA5-IRD over 6 months and to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration due to biallelic mutations in the LCA5 gene. Funding Source- FDA Office of Orphan Products Development (OOPD).

Read the detailed description

This is a non-randomized, open-label, phase 1/2 dose-escalation study evaluating untreated patients for 6 months and with three doses of OPGx-001 for the treatment of LCA5-IRD.

Enrollment will begin with a low-dose of OPGx-001 delivered via single, unilateral subretinal injection (Cohort 1) and proceed to an intermediate dose (Cohort 2) and subsequent high dose (Cohort 3). Escalation to each next cohort will proceed only after review of all data and upon recommendation by an independent data monitoring committee (IDMC).

Concurrently, 16 untreated patients will be assessed for 6 months prior to treatment to study the natural course of LCA5-IRD.

03

Conditions studied

  • LCA5

Browse trials for

Keywords

  • LCA
  • Retinal Degeneration
  • IRD
  • adeno associated virus
  • gene therapy
  • LCA5
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are willing and able to provide written (ICF) and, where appropriate, willing to sign an assent prior to any study procedures.
  2. Are willing to adhere to the clinical protocol and able to perform testing procedures.
  3. In part A participants must be 13 years of age or older at consent, for Part B, participants must be 4 years of age or older at consent with the ability to conduct the MLoMT.
  4. Carry disease-causing biallelic LCA5 gene mutations determined by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory (historic testing up to 15 years from date of consent can be considered).
  5. Visual acuity: BCVA \< 20/80 on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart (modified for low vision participants) in the eye to be treated
  6. Show evidence of detectable photoreceptors by Spectral Domain Optical Coherence Tomography (SD-OCT)
  7. Participant is a good candidate for surgery per investigator judgement
  8. Participant agrees to follow direction of investigator regarding restrictions post-surgery (Part A only).

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or individuals (women of and men) unwilling to use effective for the duration of the study, including barrier methods for the first year after product (IP) administration (Part A only).
  2. Pre-existing eye conditions or complicating systemic diseases that would preclude the planned surgery. This includes individuals who are .
  3. History of intraocular surgery for either eye within 6 months prior to planned IP administration (Part A only).
  4. Have previously received gene therapy.
  5. Have used any investigational drug or device within 90 days or 5 estimated half-lives of treatment, whichever is longer or plan to participate in another study of drug or device during the study period.
  6. History of disease which may preclude the participant from participation, or which may interfere with outcome measure testing or test results.
  7. Incapable of performing visual function testing (e.g., FST testing) for reasons other than poor vision.
  8. Any absolute to a course of oral .
  9. Any other condition that would not allow the potential participant to complete follow-up examinations during the study and, in the opinion of the Investigator, makes the potential participant unsuitable for the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Dose Group 1

    A single, unilateral, subretinal injection of low dose (1E10 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of a low dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).

    Biological: AAV8.hLCA5

  • Experimental
    Dose Group 2

    A single, unilateral, subretinal injection of an intermediate dose (3E10 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of an intermediate dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).

    Biological: AAV8.hLCA5

  • Experimental
    Dose Group 3

    A single, unilateral, subretinal injection of high dose (1E11 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of a high dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).

    Biological: AAV8.hLCA5

  • No intervention
    Part B Observational

    Part B will occur concurrently with Dose Groups 1-3. Sixteen patients will be assessed for 6 months to assess the natural course of LCA5-IRD, then will be treated with OPGx-001 which will be described in a future protocol amendment.

Interventions

  • BiologicalAAV8.hLCA5

    Adeno-associated virus vector expressing human LCA5 gene

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities

    Number of DLT events

    Time frame: 2 years

  2. Number of adverse events related to OPGx-001

    Number of AEs related to IP

    Time frame: 2 years

  3. Incidence of adverse events related to OPGx-001

    Incidence of AEs related to IP

    Time frame: 2 years

  4. Severity of adverse events related to OPGx-001

    Severity of AEs related to IP

    Time frame: 2 years

  5. Number of procedure-related adverse events

    Number of AEs related to IP administration

    Time frame: 2 years

  6. Incidence of procedure-related adverse events

    Incidence of AEs related to IP administration

    Time frame: 2 years

  7. Severity of procedure-related adverse events

    Severity of AEs related to IP administration

    Time frame: 2 years

  8. Assessment of cross-sectional spectral domain optical coherence tomography images

    Qualitative Assessment of SD-OCT image

    Time frame: 2 years

  9. Assessment of Natural course of LCA5-IRD

    Change from baseline in MLoMT

    Time frame: 6 months

  10. Assessment of Natural course of LCA5-IRD

    Change from baseline in FST

    Time frame: 6 months

  11. Assessment of Natural course of LCA5-IRD

    Change from baseline in BCVA

    Time frame: 6 months

  12. Assessment of Natural course of LCA5-IRD

    Change from baseline in FCP/Microperimetry

    Time frame: 6 months

  13. Assessment of Natural course of LCA5-IRD

    Change from baseline in SD-OCT

    Time frame: 6 months

  14. Assessment of Natural course of LCA5-IRD

    Change from baseline in pupillometry

    Time frame: 6 months

  15. Assessment of Natural course of LCA5-IRD

    Number of adverse events

    Time frame: 6 months

Secondary outcomes

  1. Change from baseline over time in Multi-luminance Orientation and Mobility Test

    Number of objects identified

    Time frame: 2 years

  2. Change from baseline over time in Dark-adapted full-field sensitivity testing

    FST

    Time frame: 2 years

  3. Change from baseline over time in best corrected visual acuity (BCVA)

    Measured using LogMAR scale

    Time frame: 2 years

  4. Change from baseline over time in visual functioning questionnaire

    Assessed by the Modified National Eye Institute Visual Functioning Questionnaire

    Time frame: 1 year

Other outcomes

  1. Microperimetry

    Mean sensitivity, in dB

    Time frame: 1 year

  2. Kinetic perimetry

    Field extent, in degrees

    Time frame: 1 year

  3. Virtual Reality Orientation and Mobility Test (VR-O&M)

    Performance over a range of light levels

    Time frame: 1 year

  4. Frequency doubling technology (FDT) perimetry (sFDT-CA)

    Time frame: 1 year

  5. Light-adapted transient pupillary light reflex (LA-TPLR)

    Time frame: 1 year

  6. Sweep visual evoked potentials (sVEPs)

    Time frame: 1 year

  7. Chromatic referential looking

    In dark-adapted patients

    Time frame: 1 year

  8. Full-field chromatic sensitivity testing (FST)

    In free view

    Time frame: 1 year

  9. Portable chromatic pupillometry Portable chromatic pupillometry

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Jun 2028, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 15, 2022
StartActual
Jun 15, 2023
Primary completionEst.
Jun 15, 2028
CompletionEst.
Jun 15, 2028
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05616793
Lead sponsor
Opus Genetics, Inc
Responsible party
Sponsor
First posted
Nov 15, 2022
Start date
Jun 15, 2023
Primary completion
Jun 15, 2028 (estimated)
Completion
Jun 15, 2028 (estimated)
Last update
Feb 19, 2026

Study contacts

Tomas Aleman, M.D.
Contact
ct.gov_inquiries@opusgtx.com
1 (215) 662-6396
Mariejel Weber
Contact
mariejel.weber@pennmedicine.upenn.edu
1 (215) 662-6396

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion